New study measures radioactive drug safety in vulnerable patients
NCT ID NCT07169825
First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times
Summary
This study looks at how much of the radioactive drug Pluvicto reaches tumors and organs in patients whose kidneys or bone marrow are not working well. About 25 people will be enrolled to check for side effects and safety. The goal is to better understand dosing in these patients, not to treat the disease directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE MARROW DYSFUNCTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?